goserelin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
pituitary hormone-release stimulating peptides 1327 65807-02-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • goserelin
  • Decapeptide I
  • zoladex
  • goserelin acetate
A synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE. Goserelin is used in treatments of malignant NEOPLASMS of the prostate, uterine fibromas, and metastatic breast cancer.
  • Molecular weight: 1269.43
  • Formula: C59H84N18O14
  • CLOGP: -5.05
  • LIPINSKI: 3
  • HAC: 32
  • HDO: 18
  • TPSA: 493.39
  • ALOGS: -4.48
  • ROTB: 33

Drug dosage:

DoseUnitRoute
0.13 mg implant

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 20 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.04 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Dec. 29, 1989 FDA ASTRAZENECA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 844.23 19.42 359 9896 81762 63397005
Metastases to bone 813.91 19.42 246 10009 20773 63457994
Metastases to liver 665.75 19.42 217 10038 23422 63455345
Neutropenia 350.09 19.42 261 9994 174744 63304023
Neoplasm progression 195.32 19.42 102 10153 36326 63442441
PIK3CA-activated mutation 172.99 19.42 39 10216 1020 63477747
Metastases to lung 172.07 19.42 68 10187 12682 63466085
Metastases to lymph nodes 155.43 19.42 56 10199 8102 63470665
Tumour marker increased 137.58 19.42 45 10210 4870 63473897
Bone lesion 137.43 19.42 47 10208 5834 63472933
Breast cancer metastatic 134.36 19.42 56 10199 11962 63466805
Metastases to skin 121.29 19.42 32 10223 1631 63477136
Disease progression 118.18 19.42 121 10134 122637 63356130
Breast cancer 116.49 19.42 81 10174 48302 63430465
Hot flush 107.86 19.42 79 10176 51080 63427687
Metastases to central nervous system 107.18 19.42 49 10206 13056 63465711
Abdominal lymphadenopathy 97.96 19.42 23 10232 722 63478045
Metastases to spine 87.91 19.42 29 10226 3220 63475547
Bone disorder 81.99 19.42 48 10207 21278 63457489
Metastases to peritoneum 78.43 19.42 27 10228 3415 63475352
Metastases to spinal cord 70.30 19.42 13 10242 120 63478647
Drug ineffective 69.14 19.42 42 10213 1044723 62434044
Invasive lobular breast carcinoma 69.00 19.42 18 10237 877 63477890
Lymphadenopathy 66.94 19.42 53 10202 38405 63440362
Neuropathy peripheral 65.38 19.42 86 10169 113581 63365186
Jaundice 63.50 19.42 46 10209 29205 63449562
Ascites 60.12 19.42 51 10204 40677 63438090
Metastases to pleura 58.82 19.42 18 10237 1567 63477200
Metastases to nervous system 57.31 19.42 10 10245 64 63478703
Carbohydrate antigen 15-3 increased 56.11 19.42 17 10238 1431 63477336
Breast cancer recurrent 54.54 19.42 22 10233 4319 63474448
Osteonecrosis of jaw 53.94 19.42 45 10210 35078 63443689
Osteolysis 48.32 19.42 18 10237 2856 63475911
Pleural neoplasm 46.40 19.42 11 10244 360 63478407
Pneumonitis 45.73 19.42 41 10214 35181 63443586
Pleural effusion 43.79 19.42 64 10191 93146 63385621
Carcinoid tumour pulmonary 43.63 19.42 11 10244 467 63478300
CYP3A4 polymorphism 42.68 19.42 8 10247 80 63478687
Invasive ductal breast carcinoma 41.63 19.42 21 10234 6937 63471830
Metastases to adrenals 38.51 19.42 11 10244 754 63478013
Neutrophil count decreased 37.66 19.42 46 10209 56360 63422407
Adnexa uteri mass 36.92 19.42 10 10245 563 63478204
Osteonecrosis 36.77 19.42 31 10224 24499 63454268
Bone pain 35.57 19.42 44 10211 54597 63424170
Osteitis condensans 35.48 19.42 6 10249 31 63478736
Leukopenia 34.75 19.42 52 10203 77238 63401529
Lymphadenopathy mediastinal 34.48 19.42 14 10241 2794 63475973
Breast mass 33.56 19.42 19 10236 7903 63470864
Merycism 33.42 19.42 8 10247 273 63478494
Hepatic lesion 33.14 19.42 16 10239 4809 63473958
Endometrial hyperplasia 32.68 19.42 10 10245 870 63477897
Oestradiol abnormal 32.58 19.42 6 10249 54 63478713
White blood cell count decreased 32.13 19.42 70 10185 139034 63339733
Alanine aminotransferase increased 32.10 19.42 59 10196 103711 63375056
Fibrous histiocytoma 32.08 19.42 9 10246 578 63478189
Metastasis 32.01 19.42 16 10239 5181 63473586
Metastatic neoplasm 31.81 19.42 15 10240 4280 63474487
Spinal pain 31.59 19.42 22 10233 13117 63465650
Aspartate aminotransferase increased 31.36 19.42 54 10201 90223 63388544
Pleural disorder 31.21 19.42 9 10246 638 63478129
Tumour flare 30.86 19.42 8 10247 380 63478387
Dermatitis 30.85 19.42 24 10231 16934 63461833
Bone marrow infiltration 30.72 19.42 9 10246 675 63478092
Mucinous breast carcinoma 29.87 19.42 5 10250 24 63478743
Oestradiol increased 29.71 19.42 6 10249 91 63478676
Condition aggravated 29.61 19.42 14 10241 402203 63076564
Selenium deficiency 29.54 19.42 5 10250 26 63478741
Arachnoid cyst 29.53 19.42 7 10248 229 63478538
Drug hypersensitivity 29.49 19.42 7 10248 310680 63168087
Mood swings 29.30 19.42 24 10231 18224 63460543
Metastases to the mediastinum 29.04 19.42 8 10247 480 63478287
Uterine mass 27.70 19.42 7 10248 300 63478467
Body surface area increased 27.35 19.42 5 10250 43 63478724
Pathological fracture 26.56 19.42 17 10238 8817 63469950
Breast cancer female 26.44 19.42 20 10235 13539 63465228
Gamma-glutamyltransferase increased 26.44 19.42 30 10225 34001 63444766
Palmar-plantar erythrodysaesthesia syndrome 26.39 19.42 25 10230 22990 63455777
Central nervous system lesion 26.02 19.42 18 10237 10617 63468150
Febrile neutropenia 25.53 19.42 58 10197 118391 63360376
Arthropathy 24.98 19.42 4 10251 234788 63243979
Metastases to ovary 24.93 19.42 7 10248 451 63478316
Mucosal inflammation 24.64 19.42 34 10221 46894 63431873
Metastases to stomach 24.49 19.42 6 10249 226 63478541
Uterine polyp 24.41 19.42 10 10245 2040 63476727
Hepatotoxicity 24.38 19.42 30 10225 37011 63441756
Cervical polyp 24.29 19.42 6 10249 234 63478533
Uterine leiomyoma 23.52 19.42 16 10239 9182 63469585
Musculoskeletal chest pain 22.47 19.42 22 10233 21061 63457706
Amenorrhoea 22.44 19.42 16 10239 9898 63468869
Hepatic cancer 22.41 19.42 12 10243 4475 63474292
Hypersensitivity 21.81 19.42 10 10245 292675 63186092
Ocular icterus 21.77 19.42 11 10244 3645 63475122
Bile duct stenosis 21.60 19.42 8 10247 1248 63477519
Depressed mood 20.92 19.42 29 10226 40162 63438605
Blood alkaline phosphatase increased 20.88 19.42 30 10225 42937 63435830
Hepatic cyst 20.86 19.42 12 10243 5142 63473625
Disturbance in attention 20.55 19.42 28 10227 38161 63440606
Lymphangioleiomyomatosis 20.45 19.42 5 10250 187 63478580
Metastases to pelvis 20.28 19.42 6 10249 465 63478302
Acute promyelocytic leukaemia 20.07 19.42 7 10248 920 63477847
Tooth extraction 19.70 19.42 15 10240 10249 63468518
Cholangitis sclerosing 19.53 19.42 8 10247 1633 63477134

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Osteonecrosis of jaw 288.37 15.33 129 10266 17760 34928776
Prostatic specific antigen increased 240.18 15.33 107 10288 14573 34931963
Metastases to bone 220.97 15.33 95 10300 11875 34934661
Malignant neoplasm progression 167.72 15.33 166 10229 87880 34858656
Prostate cancer metastatic 144.23 15.33 57 10338 5746 34940790
Hot flush 110.16 15.33 68 10327 17998 34928538
Interstitial lung disease 104.12 15.33 112 10283 65170 34881366
Osteonecrosis 103.58 15.33 61 10334 14829 34931707
Prostate cancer 79.49 15.33 77 10318 39572 34906964
Malignant spinal cord compression 60.24 15.33 13 10382 144 34946392
Osteomyelitis 56.17 15.33 43 10352 16093 34930443
Haematuria 50.31 15.33 68 10327 49998 34896538
Death 48.73 15.33 240 10155 397809 34548727
Tooth extraction 48.39 15.33 25 10370 4703 34941833
Osteitis 44.24 15.33 17 10378 1587 34944949
Pain in jaw 39.45 15.33 32 10363 13008 34933528
Bone pain 37.40 15.33 38 10357 20648 34925888
Central nervous system mass 37.23 15.33 9 10386 170 34946366
Wall motion score index abnormal 37.08 15.33 9 10386 173 34946363
Blood testosterone increased 36.93 15.33 14 10381 1259 34945277
Pituitary haemorrhage 36.24 15.33 9 10386 191 34946345
Airway remodelling 34.65 15.33 9 10386 230 34946306
Bone disorder 34.36 15.33 22 10373 6193 34940343
Atopy 34.17 15.33 9 10386 243 34946293
Pituitary tumour benign 34.16 15.33 12 10383 869 34945667
Exposed bone in jaw 33.95 15.33 14 10381 1572 34944964
Cancer pain 32.85 15.33 16 10379 2656 34943880
Hepatic function abnormal 32.59 15.33 52 10343 44311 34902225
Hypocalcaemia 32.36 15.33 38 10357 24251 34922285
Cardiac septal defect 32.07 15.33 9 10386 310 34946226
Metastases to spine 30.35 15.33 15 10380 2569 34943967
Contracted bladder 28.94 15.33 5 10390 14 34946522
Eosinophilic myocarditis 27.21 15.33 9 10386 543 34945993
Device expulsion 26.78 15.33 6 10389 80 34946456
Eosinophilic cystitis 26.03 15.33 5 10390 29 34946507
PO2 increased 25.94 15.33 9 10386 628 34945908
Drug ineffective 25.47 15.33 62 10333 456689 34489847
Gingival erythema 24.89 15.33 6 10389 112 34946424
Metastases to lymph nodes 24.33 15.33 16 10379 4712 34941824
Toxicity to various agents 23.99 15.33 15 10380 200347 34746189
Haemoglobin decreased 23.40 15.33 84 10311 120688 34825848
Purulent discharge 23.30 15.33 13 10382 2850 34943686
Gingivitis 23.16 15.33 14 10381 3561 34942975
Ubiquinone decreased 22.94 15.33 4 10391 12 34946524
Bone sequestrum 22.84 15.33 8 10387 574 34945962
Microangiopathy 22.40 15.33 9 10386 945 34945591
Urinary retention 21.94 15.33 39 10356 36249 34910287
Bone debridement 21.57 15.33 6 10389 200 34946336
Injection site haemorrhage 21.51 15.33 20 10375 9748 34936788
Arterial injury 21.10 15.33 7 10388 426 34946110
Eosinophilic pneumonia 20.87 15.33 13 10382 3488 34943048
Blood alkaline phosphatase increased 20.80 15.33 35 10360 31140 34915396
Sequestrectomy 20.79 15.33 6 10389 229 34946307
Bone lesion 20.23 15.33 12 10383 2951 34943585
PCO2 decreased 19.94 15.33 10 10385 1766 34944770
Injection site haematoma 19.90 15.33 10 10385 1775 34944761
Respiratory symptom 19.83 15.33 10 10385 1787 34944749
Terminal state 19.48 15.33 13 10382 3921 34942615
Pulmonary embolism 18.74 15.33 64 10331 89682 34856854
Hypophosphataemia 17.67 15.33 19 10376 11007 34935529
Spinal cord compression 17 15.33 12 10383 3963 34942573
Gingival swelling 16.87 15.33 8 10387 1252 34945284
Blood immunoglobulin E increased 16.57 15.33 10 10385 2536 34944000
Metastasis 16.55 15.33 12 10383 4132 34942404
Protein total decreased 16.39 15.33 13 10382 5117 34941419
Off label use 16.27 15.33 67 10328 419457 34527079
Eosinophilic granulomatosis with polyangiitis 16.11 15.33 9 10386 1978 34944558
Metastases to liver 15.95 15.33 20 10375 13643 34932893
Back pain 15.89 15.33 75 10320 121714 34824822
Breast cancer 15.41 15.33 5 10390 284 34946252

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Metastases to bone 652.24 14.96 230 16450 24197 79703511
Malignant neoplasm progression 517.49 14.96 333 16347 135657 79592051
Metastases to liver 377.38 14.96 161 16519 28153 79699555
Osteonecrosis of jaw 250.39 14.96 139 16541 43087 79684621
Neutropenia 213.68 14.96 281 16399 287429 79440279
Prostatic specific antigen increased 175.40 14.96 70 16610 10316 79717392
Hot flush 152.64 14.96 111 16569 54766 79672942
Metastases to lymph nodes 148.00 14.96 62 16618 10335 79717373
Prostate cancer metastatic 123.29 14.96 42 16638 3965 79723743
Metastases to lung 112.24 14.96 61 16619 18102 79709606
Neoplasm progression 109.62 14.96 89 16591 51593 79676115
PIK3CA-activated mutation 102.11 14.96 24 16656 579 79727129
Bone lesion 100.30 14.96 40 16640 5879 79721829
Osteonecrosis 86.65 14.96 63 16617 31032 79696676
Drug ineffective 77.15 14.96 68 16612 1080845 78646863
Prostate cancer 74.16 14.96 59 16621 33209 79694499
Interstitial lung disease 72.72 14.96 103 16577 112497 79615211
Breast mass 72.43 14.96 33 16647 6721 79720987
Breast cancer metastatic 67.76 14.96 34 16646 8568 79719140
Malignant spinal cord compression 64.63 14.96 13 16667 146 79727562
Metastases to spine 62.25 14.96 26 16654 4298 79723410
Metastases to central nervous system 61.78 14.96 40 16640 16335 79711373
Abdominal lymphadenopathy 61.49 14.96 19 16661 1315 79726393
Disease progression 57.28 14.96 122 16558 184240 79543468
Metastases to skin 56.53 14.96 19 16661 1720 79725988
Bone pain 55.02 14.96 63 16617 55679 79672029
Osteolysis 54.69 14.96 24 16656 4474 79723234
Tumour marker increased 52.61 14.96 23 16657 4249 79723459
Carbohydrate antigen 15-3 increased 51.02 14.96 16 16664 1163 79726545
Bone disorder 47.15 14.96 36 16644 19077 79708631
Breast cancer 45.42 14.96 45 16635 33736 79693972
Lymphadenopathy 42.44 14.96 54 16626 53193 79674515
Death 42.08 14.96 231 16449 566283 79161425
Wall motion score index abnormal 40.23 14.96 9 16671 173 79727535
Central nervous system mass 40.18 14.96 9 16671 174 79727534
Breast cancer recurrent 39.85 14.96 17 16663 2960 79724748
Tooth extraction 39.37 14.96 26 16654 10969 79716739
Adnexa uteri mass 38.07 14.96 10 16670 384 79727324
Infusion related reaction 36.89 14.96 3 16677 230234 79497474
Invasive lobular breast carcinoma 36.49 14.96 11 16669 700 79727008
Blood alkaline phosphatase increased 36.38 14.96 55 16625 63609 79664099
Airway remodelling 35.94 14.96 9 16671 285 79727423
Haematuria 35.88 14.96 57 16623 68779 79658929
CYP3A4 polymorphism 35.54 14.96 7 16673 70 79727638
Pituitary haemorrhage 35.44 14.96 9 16671 302 79727406
Mucinous breast carcinoma 34.80 14.96 6 16674 26 79727682
Cardiac septal defect 34.59 14.96 9 16671 333 79727375
Osteitis condensans 33.93 14.96 6 16674 31 79727677
Osteomyelitis 33.88 14.96 38 16642 32827 79694881
Atopy 32.34 14.96 9 16671 431 79727277
Osteitis 32.28 14.96 16 16664 3927 79723781
Merycism 31.86 14.96 8 16672 256 79727452
Spinal pain 31.55 14.96 26 16654 15366 79712342
Pathological fracture 30.83 14.96 22 16658 10515 79717193
Metastases to peritoneum 30.71 14.96 16 16664 4356 79723352
Completed suicide 30.51 14.96 7 16673 245760 79481948
Rheumatoid arthritis 30.10 14.96 4 16676 208466 79519242
Hepatic function abnormal 29.47 14.96 54 16626 73053 79654655
Endometrial hyperplasia 29.07 14.96 9 16671 627 79727081
Contracted bladder 28.76 14.96 5 16675 23 79727685
Hepatic lesion 28.73 14.96 18 16662 6941 79720767
Blood testosterone increased 28.39 14.96 10 16670 1042 79726666
Fibrous histiocytoma 27.98 14.96 9 16671 710 79726998
Selenium deficiency 27.10 14.96 5 16675 34 79727674
Arthropathy 26.54 14.96 3 16677 177108 79550600
Metastasis 26.42 14.96 17 16663 6863 79720845
Dental fistula 26.31 14.96 8 16672 524 79727184
Drug hypersensitivity 26.18 14.96 15 16665 298901 79428807
Cancer pain 25.33 14.96 15 16665 5230 79722478
Pleural disorder 25.31 14.96 9 16671 964 79726744
Metastases to spinal cord 25.30 14.96 5 16675 51 79727657
Metastases to the mediastinum 25.24 14.96 8 16672 602 79727106
Cervical polyp 25.13 14.96 6 16674 155 79727553
Lymphadenopathy mediastinal 25.05 14.96 14 16666 4382 79723326
Arachnoid cyst 24.96 14.96 7 16673 345 79727363
Metastases to meninges 24.79 14.96 13 16667 3588 79724120
White blood cell count decreased 24.68 14.96 91 16589 188197 79539511
Pleural neoplasm 24.65 14.96 7 16673 361 79727347
Neuropathy peripheral 24.46 14.96 75 16605 141230 79586478
Carcinoid tumour pulmonary 24.36 14.96 7 16673 377 79727331
Pulmonary embolism 23.37 14.96 84 16596 171570 79556138
Eosinophilic myocarditis 23.31 14.96 9 16671 1213 79726495
Bone sequestrum 23.26 14.96 9 16671 1220 79726488
Bone debridement 23.18 14.96 7 16673 448 79727260
Hypocalcaemia 22.86 14.96 39 16641 49885 79677823
Toxicity to various agents 22.83 14.96 33 16647 421507 79306201
Pituitary tumour benign 22.72 14.96 11 16669 2565 79725143
Alanine aminotransferase increased 22.51 14.96 80 16600 162490 79565218
Pneumonitis 22.10 14.96 43 16637 60817 79666891
Eosinophilic cystitis 21.93 14.96 5 16675 105 79727603
Hypersensitivity 21.78 14.96 14 16666 262225 79465483
Ubiquinone decreased 21.46 14.96 4 16676 29 79727679
Pleural effusion 21.43 14.96 73 16607 145189 79582519
Respiratory symptom 21.32 14.96 13 16667 4778 79722930
Metastases to pleura 21.22 14.96 9 16671 1545 79726163
Uterine polyp 21.05 14.96 9 16671 1575 79726133
PO2 increased 21.03 14.96 9 16671 1579 79726129
BRCA1 gene mutation 21.00 14.96 4 16676 33 79727675
Jaundice 20.98 14.96 39 16641 53310 79674398
Metastases to pelvis 20.60 14.96 7 16673 655 79727053
Electrocardiogram QT prolonged 20.57 14.96 53 16627 90333 79637375
Febrile neutropenia 20.41 14.96 99 16581 230900 79496808
Body surface area increased 20.36 14.96 5 16675 146 79727562
Oestradiol abnormal 20.22 14.96 4 16676 41 79727667
Gingivitis 20.10 14.96 16 16664 9005 79718703
Lymphangioleiomyomatosis 19.68 14.96 5 16675 168 79727540
Ocular icterus 19.68 14.96 13 16667 5487 79722221
Microangiopathy 19.64 14.96 9 16671 1856 79725852
Haemoglobin decreased 19.48 14.96 95 16585 222024 79505684
Neutrophil count decreased 19.27 14.96 53 16627 93906 79633802
Nasopharyngitis 19.18 14.96 15 16665 253866 79473842
Prostate cancer recurrent 19.15 14.96 7 16673 811 79726897
Exposed bone in jaw 18.92 14.96 11 16669 3709 79723999
Breast swelling 18.87 14.96 8 16672 1372 79726336
Mood swings 18.82 14.96 22 16658 19858 79707850
Metastases to nervous system 18.46 14.96 4 16676 66 79727642
Sinusitis 18.30 14.96 9 16671 195492 79532216
Decreased appetite 18.04 14.96 128 16552 342290 79385418
Application site haematoma 18.03 14.96 4 16676 74 79727634
Overdose 17.98 14.96 8 16672 184198 79543510
Gamma-glutamyltransferase increased 17.90 14.96 37 16643 54643 79673065
PCO2 decreased 17.85 14.96 10 16670 3144 79724564
Libido decreased 17.65 14.96 12 16668 5309 79722399
Breast injury 17.59 14.96 4 16676 83 79727625
Leukopenia 17.57 14.96 59 16621 116454 79611254
Lymphoedema 17.55 14.96 17 16663 12396 79715312
Joint swelling 17.25 14.96 21 16659 288625 79439083
Breast pain 17.02 14.96 14 16666 8251 79719457
Oestradiol increased 16.77 14.96 4 16676 103 79727605
Central nervous system lesion 16.49 14.96 17 16663 13351 79714357
Musculoskeletal chest pain 16.48 14.96 23 16657 24741 79702967
Menopausal symptoms 16.17 14.96 8 16672 1955 79725753
Amenorrhoea 15.78 14.96 13 16667 7679 79720029
Uterine leiomyoma 15.59 14.96 12 16668 6431 79721277
Bone trimming 15.52 14.96 3 16677 27 79727681
Platelet count decreased 15.48 14.96 81 16599 194583 79533125
Eosinophilic pneumonia 15.34 14.96 11 16669 5299 79722409
Acute promyelocytic leukaemia 15.09 14.96 7 16673 1484 79726224
Condition aggravated 15.08 14.96 54 16626 501070 79226638

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L02AE03 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ENDOCRINE THERAPY
HORMONES AND RELATED AGENTS
Gonadotropin releasing hormone analogues
FDA MoA N0000175654 Gonadotropin Releasing Hormone Receptor Agonists
FDA EPC N0000175655 Gonadotropin Releasing Hormone Receptor Agonist
MeSH PA D000970 Antineoplastic Agents
MeSH PA D018931 Antineoplastic Agents, Hormonal

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Endometriosis indication 129103003
Hormone receptor positive malignant neoplasm of breast indication 417181009
Advanced Prostatic Carcinoma indication
Endometrial Ablation Adjunct indication
Urinary tract obstruction contraindication 7163005 DOID:5200
Hypercholesterolemia contraindication 13644009
Hypertensive disorder contraindication 38341003 DOID:10763
Hypercalcemia contraindication 66931009 DOID:12678
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Pregnancy, function contraindication 289908002
Bilateral orchidectomy contraindication 386634006
Cardiovascular event risk contraindication 395112001
Breastfeeding (mother) contraindication 413712001
Obesity contraindication 414916001 DOID:9970
Smokes tobacco daily contraindication 449868002
Bone Metastases contraindication
Vertebral Metastases contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.85 acidic
pKa2 9.65 acidic
pKa3 11.9 acidic
pKa4 12.55 acidic
pKa5 13.03 acidic
pKa6 13.27 acidic
pKa7 13.43 acidic
pKa8 10.75 Basic
pKa9 6.69 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Gonadotropin-releasing hormone receptor GPCR AGONIST CHEMBL CHEMBL
Lutropin-choriogonadotropic hormone receptor GPCR WOMBAT-PK

External reference:

IDSource
N0000007256 NUI
D00573 KEGG_DRUG
145781-92-6 SECONDARY_CAS_RN
4019508 VANDF
C0120107 UMLSCUI
CHEBI:5523 CHEBI
CHEMBL1201247 ChEMBL_ID
CHEMBL1200501 ChEMBL_ID
D017273 MESH_DESCRIPTOR_UI
DB00014 DRUGBANK_ID
3879 IUPHAR_LIGAND_ID
5943 INN_ID
0F65R8P09N UNII
5311128 PUBCHEM_CID
203146 RXNORM
1550 MMSL
4799 MMSL
d01354 MMSL
003532 NDDF
006407 NDDF
008308 NDDF
008309 NDDF
108771008 SNOMEDCT_US
108773006 SNOMEDCT_US
126138002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ZOLADEX HUMAN PRESCRIPTION DRUG LABEL 1 50090-3466 IMPLANT 3.60 mg SUBCUTANEOUS NDA 26 sections
ZOLADEX HUMAN PRESCRIPTION DRUG LABEL 1 70720-950 IMPLANT 3.60 mg SUBCUTANEOUS NDA 27 sections
ZOLADEX HUMAN PRESCRIPTION DRUG LABEL 1 70720-950 IMPLANT 3.60 mg SUBCUTANEOUS NDA 27 sections
ZOLADEX HUMAN PRESCRIPTION DRUG LABEL 1 70720-950 IMPLANT 3.60 mg SUBCUTANEOUS NDA 27 sections
ZOLADEX HUMAN PRESCRIPTION DRUG LABEL 1 70720-951 IMPLANT 10.80 mg SUBCUTANEOUS NDA 26 sections
ZOLADEX HUMAN PRESCRIPTION DRUG LABEL 1 70720-951 IMPLANT 10.80 mg SUBCUTANEOUS NDA 26 sections